A detailed history of Covington Capital Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Covington Capital Management holds 412 shares of VRTX stock, worth $207,009. This represents 0.0% of its overall portfolio holdings.

Number of Shares
412
Previous 487 15.4%
Holding current value
$207,009
Previous $137,000 13.14%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $20,537 - $22,914
-75 Reduced 15.4%
412 $119,000
Q2 2022

Jul 08, 2022

SELL
$234.96 - $292.55 $8,928 - $11,116
-38 Reduced 7.24%
487 $137,000
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $40,077 - $47,235
181 Added 52.62%
525 $137,000
Q4 2021

Feb 16, 2022

SELL
$177.01 - $223.45 $9,735 - $12,289
-55 Reduced 13.78%
344 $76,000
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $5,441 - $6,089
30 Added 8.13%
399 $72,000
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $50,434 - $59,475
269 Added 269.0%
369 $74,000
Q1 2021

May 14, 2021

BUY
$207.02 - $241.31 $5,175 - $6,032
25 Added 33.33%
100 $21,000
Q1 2020

May 13, 2020

SELL
$199.77 - $247.81 $6,792 - $8,425
-34 Reduced 31.19%
75 $18,000
Q4 2019

Feb 18, 2020

BUY
$166.71 - $223.91 $5,668 - $7,612
34 Added 45.33%
109 $24,000
Q3 2019

Nov 18, 2019

SELL
$166.23 - $187.09 $3,324 - $3,741
-20 Reduced 21.05%
75 $13,000
Q1 2019

May 15, 2019

BUY
$163.73 - $194.7 $3,274 - $3,894
20 Added 26.67%
95 $17,000
Q3 2018

Nov 15, 2018

SELL
$167.73 - $192.74 $19,456 - $22,357
-116 Reduced 60.73%
75 $14,000
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $15,924 - $18,043
116 Added 154.67%
191 $29,000
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $11,109 - $12,168
75
75 $11,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Covington Capital Management Portfolio

Follow Covington Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Covington Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Covington Capital Management with notifications on news.